Posted On: 02/05/2016 12:46:04 AM
Post# of 30066
Re: All Aboard #22228
Nice. Not only did it significantly decreased LID in patients, but reversed the defect in locomotor activity.
"Recently, it has been shown that the 5-HT1A/1B receptor agonist, eltoprazine, significantly decreased LIDs in experimental PD and human patients."
"Recently, it has been shown that the 5-HT1A/1B receptor agonist, eltoprazine, significantly decreased LIDs in experimental PD and human patients."
Quote:
"We found that a defect in locomotor activity in parkinsonian and L-DOPA-treated rats was reversed by eltoprazine treatment."
(0)
(0)
